1100 Melville Street
Vancouver, BC V6E 4A6
Secteur d’activité: Biotechnology
Employés à temps plein:
|Nom||Titre||Payer||Exercé||Année de naissance|
|Ms. Carolyn M. Cross C.F.A., CFA, M.B.A., MBA||Founder, CEO & Exec. Director||643,37k||S.O.||S.O.|
|Dr. Nicolas G. Loebel Ph.D.||Pres, CTO & Exec. Director||751,64k||S.O.||S.O.|
|Dr. Simon Sinclair||Chief Medical Officer & Director||93,74k||S.O.||S.O.|
|Mr. Vipul Shah||VP & CFO||S.O.||S.O.||S.O.|
|Angelika Vance||VP of Corp. Communications||S.O.||S.O.||S.O.|
|Mr. Thomas Dawson||Sr. VP of Corp. Devel.||S.O.||S.O.||S.O.|
|Mr. Nikita Parkhaev||Company Sec.||S.O.||S.O.||S.O.|
Ondine Biomedical Inc., a Life sciences company, engages in the research, development, and commercialization of antimicrobial photodisinfection therapies in Canada and internationally. Its product platform is Photodisinfection, a topical light-based antimicrobial technology that eliminates harmful pathogens. The company's lead product is Steriwave, a photodisinfection-based medical device that eliminates harmful nasal pathogens, which leads to healthcare-associated infections. Its product pipeline also includes development of a topical antiviral therapy for the upper respiratory tract that reduces viral titres and transmission of respiratory viruses, such as SARS-CoV-2, influenza, RSV, etc.; a solution for treatment of chronic rhinosinusitis; a solution for disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia; and a solution for decolonization of burns and wounds. The company was incorporated in 1996 and is headquartered in Vancouver, Canada.
L’ISS Governance QualityScore de Ondine Biomedical Inc. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..